TAK 580

Drug Profile

TAK 580

Alternative Names: AMG-2112819; BIIB-024; MLN-2480

Latest Information Update: 13 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biogen Idec; Sunesis Pharmaceuticals
  • Developer Dana-Farber Cancer Institute; Sunesis Pharmaceuticals; Takeda Oncology
  • Class Antineoplastics
  • Mechanism of Action Raf kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Solid tumours
  • Phase I/II Glioma
  • Phase I Malignant melanoma

Most Recent Events

  • 28 Feb 2018 Phase-I/II clinical trials in Glioma (In adolescents, In children, In infants) in USA (PO) (NCT03429803)
  • 28 Feb 2018 Phase-I/II clinical trials in Solid tumours (In adolescents, In children, In infants) in USA (PO) (NCT03429803)
  • 12 Feb 2018 Dana-Farber Cancer Institute in collaboration with Millennium Pharmaceuticals plans a phase I/II trial for Glioma in USA (NCT03429803)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top